Lymphoma and myeloma are two common hematologic malignancies (blood cancers). Lymphoma ranks in the top ten most common malignant tumors in China, while myeloma is the second most common malignant tumor of the blood system. Incidences of myeloma in China are increasing each year.
The onset of malignant tumors can often go by undetected, and symptoms are not typical. Patients diagnosed with such conditions may wonder, “What are the most up-to-date international treatments? How am I going to access the best treatment plan for me?”
To address these needs, Jiahui International Cancer Center and Mass General Cancer Center will jointly open an international second opinion clinic for lymphoma/myeloma patients. The clinic will be open on March 11th 2019, 9 a.m. – 12 p.m. at Jiahui International Hospital. At the clinic, patients will be able to:
- receive treatment in a multidisciplinary treatment (MDT) setting, consisting of joint early intervention and decision making by an international, multidisciplinary team
- obtain a second opinion, face to face with international experts on myeloma/lymphoma from Mass General, Harvard’s larg est and oldest teaching hospital, without having to travel abroad
- receive a comprehensive and individualized treatment plan collaboratively drawn up by experts at Jiahui International Cancer Center and Mass General Cancer Center
- discuss comprehensive pain management and palliative care options with international experts
Clinic Opening Time/Slots
9 a.m.-12 p.m., March 11th 2019: 3 slots available for each physician from Mass General and Jiahui Health.
Clinic Consultation Price: 9,800 RMB
Consultation process:
- Before the consultation, the JICC clinical team will collect the patient’s medical records and review them with the Mass General doctor.
- During the consultation, the JICC doctor and Mass General doctor will partner together to provide recommendations.
- After the consultation, notes written by the Mass General doctor will be translated into Chinese and sent to the patient.
For inquiries and appointments, please call our lymphoma/myeloma clinic hotline: 021-5339 3128 (open Mon to Fri 8 a.m. - 8 p.m.) After office hours, please leave a voice message; our cancer nurse will call you back on a work day.
Mass General Visiting Physicians
Dr. Ephraim Hochberg, MD is a graduate of Yale University and Case Western Reserve University School of Medicine. He completed his internship and residency in medicine at the Brigham and Women’s Hospital and then trained in Hematology and Oncology at the Dana Farber Cancer Institute Fellowship Program. He has been a clinical lymphoma attending physician at Massachusetts General Hospital Cancer Center since 2003. He is currently the Associate Chief of the Massachusetts General Hospital Cancer Center and an Assistant Professor of Medicine at Harvard Medical School. His clinical and research interests are in novel agents for the therapy of lymphoid malignancies.
Dr. Noopur S. Raje, MD
Dr. Noopur Raje is a Professor of Medicine at Harvard Medical School, Director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. She is a physician scientist with a primary focus on multiple myeloma and related plasma cell disorders. Dr. Raje has focused on developing new promising therapies for Multiple Myeloma. Her laboratory efforts are aimed at identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and designing trials to specifically harness these. She is the co-chair of the National Cancer Institute steering committee for Multiple Myeloma and a board member of the International Myeloma Society.
Dr. Jeremy Abramson, MD
Dr. Jeremy Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Assistant Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters of Medical Sciences in Clinical Investigation from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson's clinical and research interests are in novel therapeutics and cellular immunotherapy for lymphoid malignancies.
Dr. Mihir M. Kamadar, MD
Dr. Mihir M. Kamdar, MD, is Director of the Massachusetts General Hospital Cancer Pain Clinic and Associate Director of the Division of Palliative Care and Geriatrics at Mass General, with a dual appointment in the Mass General Department of Anesthesia, Critical Care and Pain Medicine. He is an internationally recognized medical educator and researcher in palliative care and pain medicine, with clinical interests in developing novel strategies to better treat patients with cancer-related pain, and in defining the value of integrating palliative care into the care of patients with incurable cancers. He is a co-creator of ePAL, a novel smartphone app with AI technology that has been demonstrated to significantly improve cancer pain outcomes. Dr. Kamdar received his MD from Emory University School of Medicine, where he graduated magna cum laude.He subsequently completed a residency in Internal Medicine at Brigham and Women’s Hospital, a fellowship in Palliative Medicine at the HMS combined program and a fellowship in Anesthesia Pain Medicine at Mass General. He is on faculty at Harvard Medical School.
Jiahui Physicians
Dr. Lily Zhou, MD, PhD
Dr. Anna Li, MD
Dr. David Jiang, MD
